Table 2. Sensitivity analysis.

Design/effect	Study (year)	HR	LL	UL
Aspirin postdiagnosis
All-cause mortality		0.74	0.62	0.89
	Reimers et al, 2014	0.79	0.66	0.94
	McCowan et al, 2012	0.77	0.63	0.95
	Walker et al, 2012	0.69	0.61	0.79
	Liao et al, 2012	0.74	0.61	0.91
	Chan et al, 2009	0.73	0.57	0.93
Colorectal cancer-specific mortality		0.75	0.51	1.10
	Cardwell et al, 2014	0.63	0.52	0.76
	McCowan et al, 2012	0.86	0.59	1.24
	Liao et al, 2012	0.77	0.52	1.14
	Chan et al, 2009	0.75	0.43	1.31
Users prediagnosis
All-cause mortality		0.88	0.83	0.93
	Walker et al, 2012	0.88	0.83	0.93
	Liao et al, 2012	0.88	0.83	0.93
	Chan et al, 2009	0.87	0.83	0.92
	Bastiaannet et al, 2012	0.87	0.78	0.97
Colorectal cancer-specific mortality		0.80	0.59	1.09
	Cardwell et al, 2014	0.86	0.57	1.28
	Liao et al, 2012	0.82	0.59	1.12
	Chan et al, 2009	0.70	0.43	1.11
Nonusers prediagnosis
All-cause mortality		0.84	0.70	1.00
	Walker et al, 2012	0.77	0.66	0.89
	Liao et al, 2012	0.82	0.66	1.03
	Chan et al, 2009	0.89	0.75	1.05
	Bastiaannet et al, 2012	0.86	0.68	1.09
Colorectal cancer-specific mortality		0.79	0.61	1.02
	Cardwell et al, 2014	0.58	0.38	0.88
	Liao et al, 2012	0.79	0.60	1.03
	Chan et al, 2009	0.92	0.68	1.24

Abbreviations: HR=hazard ratio; LL=lower limit; UL=upper limit.